Evogene Ltd. (EVGN)

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD); and with ELEO, Inc. to develop oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases. The company was incorporated in 1999 and is headquartered in Rehovot, Israel.

Ticker
EVGN
Exchange
Nasdaq
Sector
Healthcare
Industry
Biotechnology
Market cap
$9.20M
52-week range
$0.25 - $1.26

Valuation

Share price
$0.35 (close of Nov 18, 2026)
P/E (TTM)
-0.75x
Price to book
1.60x
Price to free cash flow
-0.84x
Enterprise value
$1.99M
Book value per share
$0.21

Price performance

PeriodChange
1 day+2.94%
5 days-12.50%
1 month-10.26%
3 months-39.66%
6 months-50.00%
Year to date-68.18%
1 year-70.09%
3 years-94.70%
5 years-98.33%
10 years-99.40%
All time-99.64%

Short interest

As of
Oct 30, 2026
Short % of float
0.39%
Shares short
70.32K
Days to cover
2.33
Change since prior report
+10.08%
Source
FINRA consolidated short interest

Profitability and growth

Return on equity
-70.86%
Return on invested capital
-99.02%
Return on assets
-42.33%
Return on capital employed
-84.53%
Gross margin
-6.25%
Net margin
-220.22%
EBITDA margin
-350.69%
Revenue growth
-30.91%

Cash flow and balance sheet

Free cash flow yield (TTM)
-119.18%
Current ratio
3.57x
Net debt to EBITDA
0.64x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$3.85M
Cost of revenue
$4.09M
Gross profit
-$241.00K
EBITDA
-$13.51M
Net income
-$8.48M
Research and development
$7.99M
Interest expense
$1.93M

Income statement by year

Period endRevenueGross profitNet income
2025-12-31$3.85M-$241.00K-$8.48M
2024-12-31$5.58M--$16.48M
2023-12-31$2.98M--$23.88M
2022-12-31$1.68M--$26.64M
2021-12-31$930.00K--$27.79M
2020-12-31$1.04M--$23.37M
2019-12-31$753.00K--$18.11M
2018-12-31$1.75M--$20.76M
2017-12-31$3.38M--$20.84M
2016-12-31$6.54M--$19.59M

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-31-6.25%-220.22%-70.86%-99.02%
2024-12-31--295.59%-111.10%-67.86%
2023-12-31--800.77%-83.25%-55.31%
2022-12-31--1,590.33%-76.57%-57.66%
2021-12-31--2,988.49%-43.82%-46.84%
2020-12-31--2,247.50%-41.09%-41.83%
2019-12-31--2,405.31%-30.08%-33.50%
2018-12-31--1,188.21%-41.26%-39.73%
2017-12-31--616.33%-30.04%-31.63%
2016-12-31--299.57%-22.44%-24.16%

Cash and debt by year

Period endCash
2025-12-31$12.96M
2024-12-31$15.30M
2023-12-31$20.77M
2022-12-31$28.98M
2021-12-31$32.33M
2020-12-31$46.23M
2019-12-31$34.75M
2018-12-31$5.81M
2017-12-31$3.44M
2016-12-31$3.24M

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31-$13.64M$654.00K
2024-12-31-$20.33M$1.24M
2023-12-31-$22.15M$1.11M
2022-12-31-$24.85M$1.19M
2021-12-31-$25.56M$2.61M
2020-12-31-$20.20M$4.10M
2019-12-31-$18.57M$1.58M
2018-12-31-$15.54M$1.73M
2017-12-31-$16.52M$2.24M
2016-12-31-$12.50M$2.94M

Investor relations

Next earnings report

Next confirmed report
Nov 19, 2026
Consensus EPS estimate
$-0.19

Past earnings dates

ReportedFiscal periodEPS estimate
2026-08-18Jun 2026-
2026-05-20Mar 2026-
2026-03-05Dec 2025-
2025-11-20Sep 2025-
2025-08-19Jun 2025-
2025-05-21Mar 2025-
2025-03-06Dec 2024-
2024-11-21Sep 2024-

Filings and sources

Company website
evogene.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Insmed Inc (INSM) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades